Summary
38 / 100 · Bulios Score
What speaks for it
- Revenue grew by 32% a year over the last 3 years.
- It holds more cash than debt: $122.4M against $18.5M.
- The share price is below the Bulios Fair Price.
What to watch
- The company made a loss over the last 12 months.
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue fell by 11% a year over 5 years. Over the last 3 years it grew by 32% a year.
Growth in detailDoes it make money?
PoorlyWhere 100 USD of revenue goes
- Cost of sales -314 USD
- Research and development 1,031 USD
- Sales and administration 1,033 USD
- Taxes and other -1,660 USD
- Net profit 12 USD
Net profit, industry median (Biotechnology) -7.3 USD
Out of every 100 USD of revenue, 12 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesOver the last 12 months it spent more cash than it brought in. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 2
- Hold 0
- Sell 0
No analyst has published a price target.
100% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.